Education
About Us
Working with TipRanks
Follow Us
SYNB - ETF AI Analysis
Top Page
Putnam BioRevolution ETF (SYNB)
Rating:66Neutral
Price Target:
$34.00
Positive Factors
Strong Top Holdings
Several key holdings, such as Nvidia, AbbVie, and Ascendis Pharma, have shown strong year-to-date performance, driving the ETF's returns.
Sector Focus on Health Care
With over 60% exposure to the health care sector, the ETF benefits from a focus on a historically resilient and growing industry.
Solid Recent Performance
The ETF has delivered steady gains over the past month, three months, and year-to-date, indicating positive momentum.
Negative Factors
High Geographic Concentration
The ETF is heavily concentrated in U.S. companies, with over 90% exposure, limiting diversification across global markets.
Relatively High Expense Ratio
The fund charges a 0.7% expense ratio, which is higher than many ETFs and could eat into long-term returns.
Underperforming Holdings
Some holdings, such as Bio-Rad Laboratories and Eli Lilly, have shown weaker year-to-date performance, potentially dragging on overall results.
SYNB vs. SPDR S&P 500 ETF (SPY)
AUM3.08M
RegionGlobal
Expense Ratio0.70%
Beta0.79
IssuerPutnam
Inception DateSep 29, 2022
Dividend Yield0.7%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume234
30 Day Avg. Volume993
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
36.63Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering35
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SYNB Summary
The Putnam BioRevolution ETF (SYNB) is an investment fund focused on companies leading advancements in genomic research and biotechnology. It includes firms working on gene editing, personalized medicine, and synthetic biology, with well-known names like Thermo Fisher and AbbVie among its top holdings. This ETF is ideal for investors looking to support innovation in healthcare and potentially benefit from the growth of cutting-edge technologies. However, it’s important to know that the fund is heavily tied to the health care and biotech sectors, meaning its performance could be affected by changes in those industries or regulatory challenges.
How much will it cost me?The Putnam BioRevolution ETF (SYNB) has an expense ratio of 0.7%, which means you’ll pay $7 per year for every $1,000 invested. This is higher than average because it is an actively managed fund focusing on a specialized niche in genomic advancements, requiring more research and expertise to manage.
What would affect this ETF?The Putnam BioRevolution ETF could benefit from advancements in genomic research and personalized medicine, as well as increased global investment in biotechnology and healthcare innovation. However, it may face challenges from regulatory hurdles, fluctuating interest rates, or economic downturns that could impact funding and growth in the biotech sector. Additionally, reliance on cutting-edge technologies like gene editing and synthetic biology may expose the ETF to risks associated with slower-than-expected adoption or technical setbacks.
SYNB Top 10 Holdings
The Putnam BioRevolution ETF is heavily concentrated in the healthcare sector, with standout performers like Bio-Rad Laboratories and Ascendis Pharma driving gains thanks to their focus on innovative technologies and strong earnings momentum. Nvidia adds a tech twist to the fund, benefiting from its AI infrastructure leadership, though its high valuation raises some concerns. On the flip side, Corteva and Cadence Design have been lagging, with bearish momentum and valuation challenges weighing on their performance. With a global mix of holdings, this ETF is a bet on the future of genomic and biotech innovation.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Thermo Fisher | 9.37% | $287.92K | $212.64B | 2.58% | 73 Outperform | |
| ― | 6.11% | $187.59K | ― | ― | ― | |
| AbbVie | 5.46% | $167.88K | $387.13B | 9.79% | 62 Neutral | |
| Corteva | 5.17% | $158.77K | $42.67B | 9.98% | 75 Outperform | |
| Novonesis | 4.94% | $151.87K | $29.92B | 5.02% | 64 Neutral | |
| Nvidia | 4.84% | $148.64K | $4.57T | 27.45% | 85 Outperform | |
| Ascendis Pharma | 4.66% | $143.16K | $12.07B | 57.47% | 61 Neutral | |
| AstraZeneca | 4.63% | $142.26K | $261.81B | 31.15% | 75 Outperform | |
| Bio-Rad Laboratories | 4.63% | $142.09K | $8.26B | -17.25% | 58 Neutral | |
| Eli Lilly & Co | 4.27% | $131.26K | $886.24B | 11.16% | 76 Outperform |
SYNB Technical Analysis
Positive
―
Price Trends
30.56
Positive
29.90
Positive
29.09
Positive
Market Momentum
0.05
Positive
44.89
Neutral
5.70
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SYNB, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 31.06, equal to the 50-day MA of 30.56, and equal to the 200-day MA of 29.09, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 44.89 is Neutral, neither overbought nor oversold. The STOCH value of 5.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYNB.
SYNB Peer Comparison
Comparison Results
Performance Comparison
SYNB
Putnam BioRevolution ETF
30.62
-0.58
-1.86%
AGIX
KraneShares Artificial Intelligence & Technology ETF
―
―
―
AIFD
TCW Artificial Intelligence ETF
―
―
―
YNOT
Horizon Digital Frontier ETF
―
―
―
IQM
Franklin Intelligent Machines ETF
―
―
―
HELX
Franklin Genomic Advancements ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents